Scientists have found a natural molecule that might help prevent vision loss. This molecule, called erucamide, seems to help the retina respond to damage from eye diseases. This discovery could lead to new ways to slow down vision loss.
Millions of people suffer from conditions like age-related macular degeneration, diabetic retinopathy, and retinitis pigmentosa. These diseases often cause vision loss as light-sensing cells in the eye, called photoreceptors, slowly die.
Instead of just treating symptoms, researchers are looking for ways to boost the retina's natural ability to protect itself.
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News DetoxErucamide: The Retina's Natural Defender
A new study suggests erucamide plays a key role in this protection. Scientists at Scripps Research, along with UC San Diego and the Lowy Medical Research Institute, found that erucamide is important for how retinal cells communicate.
Their findings, published in Nature Neuroscience, show that erucamide levels drop when photoreceptors start to die. When the molecule was restored, it triggered protective responses in cells, which helped stabilize the retinal tissue. This suggests erucamide is part of the retina's natural defense system.
Martin Friedlander, a professor at Scripps Research and senior author, explained that the retina doesn't just get worse; it actively fights injury. He noted that erucamide helps coordinate this response.
Healthy vision relies on constant communication between different cells in the eye, forming a network called the neurovascular unit. In diseases like diabetic retinopathy and macular degeneration, this communication breaks down, leading to vision loss as photoreceptors are lost.
Friedlander's team had previously found that transplanted stem cells could slow degeneration even after they were gone. This hinted that the cells released protective molecules. The new study aimed to find these signals.
Many lipid molecules act as messengers in the body, but some have been overlooked in eye research. The team used a method called mass spectrometry-based metabolomics to measure many small molecules in tissue samples.
They studied models of retinal degeneration and watched how molecular levels changed as the disease progressed. Erucamide stood out because its levels dropped significantly as photoreceptors deteriorated. This suggested it was directly linked to the disease process.
Co-author Dale Boger, a chemistry professor at Scripps Research, called this a "pivotal moment." It raised the idea that erucamide might influence how tissue responds, rather than just changing as a result of the disease.
How Erucamide Works
To see if restoring erucamide could help, researchers delivered the molecule into the eye using tiny porous silicon nanoparticles. These carriers released the compound in a controlled way.
Erucamide doesn't dissolve well in water and tends to clump. The nanoparticles kept it stable and spread evenly.
The molecule didn't act directly on photoreceptors. Instead, it activated CD11b⁺ myeloid cells, which are immune cells in the retina that respond to injury. The team also found a protein called TMEM19 that binds to erucamide. When TMEM19 levels were lowered, the myeloid cells weren't activated, and erucamide's protective effects disappeared.
Once activated, the myeloid cells released signals that helped stabilize nerve cells and blood vessels in the retina. Erucamide didn't reverse damage, but it slowed some aspects of degeneration by protecting the remaining tissue.
Guoqin Wei, the first author, explained that erucamide works by affecting the surrounding environment, not just the photoreceptors. This new perspective could be important for treating degenerative retinal diseases.
Looking Ahead
More research is needed to fully understand how erucamide works. Future studies will explore its role in different retinal diseases and see if targeting this pathway can offer lasting benefits.
A challenge is that erucamide is hydrophobic, while most eye medications are water-based. Researchers plan to improve delivery methods and test modified versions of erucamide for stronger effects. They will also look into related lipid molecules that might be even more effective.
These findings suggest that natural molecules in the body could help tissues withstand disease. This points to a new strategy for slowing retinal degeneration by boosting the retina's own protective systems.
Friedlander noted that the goal is to strengthen a signal that's already there. He believes that carefully adjusting this response could offer a new way to slow down retinal diseases where treatment options are currently limited.
Deep Dive & References
A fatty acid amide activates myeloid cells and improves neurovascular outcomes in retinal degeneration - Nature Neuroscience, 2026
